ClinicalTrials.gg
CompletedNCT04021290Updated Oct 19, 2023Results posted

Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)

A Phase 3 interventional study of DTG/3TC FDC and CAR in HIV Infections, sponsored by ViiV Healthcare. Completed at 119 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-19.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.

Enrollment
11th of 55
493 · median 126
Started
2019
with 7 others
Phase 3
21 of 55
2 open now
Registered
38th of 55
by date
Lead sponsor
26 of 55
ViiV Healthcare

Among the 55 studies testing dolutegravir in HIV Infections, this one is the 11th largest by enrollment, is one of 8 that started in 2019, is one of 21 in phase 3, and was the 38th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dolutegravir

Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing dolutegravir in HIV Infections, or all of them as a file.
02

Study summary

The aim of this study is to determine if virologically suppressed Human Immunodeficiency Virus (HIV) Type 1 infected adults on a current antiretroviral regimen (CAR) (including 2 nucleoside reverse transcriptase inhibitors [NRTIs] plus a third agent) remain suppressed upon switching to dolutegravir/lamivudine (DTG/3TC) fixed dose combination (FDC). The main objective of the study is to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks in virologically suppressed adults living with HIV-1. The study will also evaluate information regarding the safety and health related quality of life. The study will include Screening Phase (up to 28 days), a Randomization Phase (up to Week 52) and a Continuation Phase (post Week 52). The Continuation Phase is not applicable for participants in Sweden and Denmark. Approximately 490 participants will be randomized in 1:1 ratio to receive DTG/3TC FDC once daily for up to 52 weeks or continue their CAR for 52 weeks. Participants in the DTG/3TC FDC arm who successfully complete up to 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in Continuation Phase.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Current antiretroviral regimen (CAR)
  • HIV-1
  • Long-term antiviral activity
  • Dolutegravir/lamivudine
  • Fixed dose combination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible participants must be able to understand and comply with protocol requirements, instructions, and restrictions; participant must be likely to complete the study as planned; participants should be considered appropriate candidates for participation in an investigative clinical trial with oral medication (example given [e.g.] no active problematic substance abuse, acute major organ disease, or potential long-term work assignments out of the country).
  • Participant should be aged 18 years or older (or older, if required by local regulatory agencies), at the time of signing the .
  • Participants living with .
  • Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening.
  • Plasma HIV-1 RNA \<50 c/mL at Screening.
  • Participant must be on uninterrupted current regimen (either the initial or second Combination antiretroviral therapy [cART] regimen) for at least 3 months prior to Screening.

    i) Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns or access to medications, or convenience/simplification and must not have been done for suspected or established treatment failure. The following switches, if they are the only switches, would not be considered a change in regimen. a) A switch from a PI boosted with ritonavir (RTV) to the same PI boosted with cobicistat is allowed (and vice versa). b) A switch from 3TC to emtricitabine (FTC) (and vice versa). c) A switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) (and vice versa).

ii) Acceptable stable cART regimens prior to Screening include 2 NRTIs plus a) INI (either the initial or second cART regimen) b) NNRTI (either the initial or second cART regimen) c) Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen).

  • A male or female participant.
  • A female participant is eligible to participate if she is not pregnant [as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at screen and a negative urine hCG test at randomization (a local serum hCG test at randomization is allowed if it can be done, and results obtained, within 24 hours prior to randomization)], not breastfeeding, and at least one of the following conditions applies; not a woman of (WOCBP) or a WOCBP who agrees to follow the guidance during the treatment period from 28 days prior to the first dose of study medication and for at least 2 weeks after the last dose of study medication. All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner; The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Participant must be capable of giving signed informed consent.
  • Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breastfeeding or plan to become pregnant or breastfeed during the study.
  • Any evidence of an active Centers for Disease Control and Prevention (CDC) Stage 3 disease except cutaneous Kaposi's sarcoma not requiring systemic therapy. Historical or current less than 200 cells per cubic millimeter (mm\^3) are not exclusionary.
  • Participants with severe hepatic impairment (Class C) as determined by classification.
  • Participants with unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Participants with the evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antigen antibody (anti-HBs) and HBV deoxyribonucleic acid (DNA) as follows: Participants positive for HBsAg are excluded; Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded. Participant's positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded. Anti-HBc must be either total anti-HBc or anti-HBc immunoglobulin G (IgG), and not anti-HBc Immunoglobulin M (IgM). Participants with a documented history of chronic HBV and current undetectable HBV DNA while on a TAF/TDF regimen are excluded.
  • Participants with anticipated need for any virus (HCV) therapy during the randomized phase of the study, or anticipated need for HCV therapy with a potential for adverse drug-drug interactions with DTG or 3TC.
  • Participants with untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment). Participants who are at least 7 days post completed treatment are eligible.
  • Participants with history or presence of allergy intolerance to the study interventions or their components or drugs of their class.
  • Participants with ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia.
  • Participants who in the investigator's judgment, poses a significant suicidality risk.
  • Participants with any pre-existing physical or mental condition which, in the opinion of the Investigator, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study interventions or render the participant unable to take oral medication.
  • Use of any regimen consisting of single or dual ART (peri-partum treatment with single dose nevirapine is allowed).
  • Participants with current use of stavudine, didanosine, or nelfinavir.
  • Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Participants receiving treatment with an -1 immunotherapeutic vaccine within 90 days of Screening.
  • Participants receiving treatment with any of the following agents within 28 days of Screening like radiation therapy; cytotoxic chemotherapeutic agents; any systemic immune suppressant.
  • Participants with exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of product (IP).
  • Any evidence of major NRTI mutation or presence of any DTG resistance-associated mutation in any available prior resistance genotype assay test result, if known.
  • Participants with any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities. A single repeat test is allowed during the Screening period to verify a result.
  • Participants with (ALT) >= 5 times the (ULN) or ALT >= 3 times ULN and >= 1.5 times ULN (with >35 percent direct bilirubin).
  • Participants with of \<30 mL/min/1.73m\^2 via Chronic Kidney Disease Epidemiology Collaboration () method. Participants with creatinine clearance between 30 to 49 mL/min/1.73 m\^2 are eligible after the medical monitor has provided approval after reviewing participant's current ART regimen.
  • Participants with any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant'sparticipation in the study of an investigational compound.
  • Participants within the 12 month window prior to Screening and after confirmed suppression to \<50 c/mL, any plasma HIV-1 RNA measurement >200 c/mL.
  • Participants within the 12 month window prior to Screening and after confirmed suppression to \<50 c/mL, 2 or more consecutive plasma HIV-1 RNA measurements >=50 c/mL. A single plasma HIV-1 RNA measurement >50 c/mL but less than 200 c/mL, with confirmation of return to \<50 c/mL is allowed.
  • Any history of switch to another regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV-1 RNA >=400 c/mL).
  • Participants with any drug holiday during the 6 months prior to Screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns.
  • Participants who are currently participating in or anticipate to be selected for any other interventional study after randomization.
  • Participants enrolled in France (or in other countries as required by local regulations or Ethics Committee/Institutional Review Board [IRB]) who participated in any study using an investigational drug or vaccine during the previous 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening for the study, or participate simultaneously in another clinical study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    Participants receiving DTG/3TC FDC

    Eligible participants will be randomized to receive 50 milligrams (mg)/300 mg DTG/3TC FDC therapy from Day 1 up to 52 weeks. Participants who complete 52 weeks of treatment will have the opportunity to continue receiving DTG/3TC FDC once daily in the continuation phase.

    Drug: DTG/3TC FDC

  • Active comparator
    Participants receiving CAR

    Eligible participants will continue to receive CAR from Day 1 up to 52 weeks.

    Drug: CAR

Interventions

  • DrugDTG/3TC FDC

    Drug pages: Dolutegravir · Lamivudine

    DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.

  • DrugCAR

    Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48

    Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: Week 48

Secondary outcomes

  1. Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48

    Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: Week 48

  2. Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24

    Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: Week 24

  3. Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24

    Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

    Time frame: Week 24

  4. Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

    Time frame: Baseline (Day 1) and Week 24

  5. Change From Baseline in CD4+ Cell Count for Week 48

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

    Time frame: Baseline (Day 1) and Week 48

  6. Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24

    CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

    Time frame: Baseline (Day 1) and Week 24

  7. Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48

    CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

    Time frame: Baseline (Day 1) and Week 48

  8. Number of Participants With Disease Progression Through Week 24

    Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.

    Time frame: Up to Week 24

  9. Number of Participants With Disease Progression Through Week 48

    Participants with disease progression included incidences of HIV-associated conditions, AIDS and death. HIV-associated conditions were assessed according to the 2014 HIV infection by CDC classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.

    Time frame: Up to Week 48

  10. Number of Participants With Adverse Events (AEs) and AEs Leading to Discontinuation

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to Week 52

  11. Number of Participants With AEs by Severity Grades

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms

    Time frame: Up to 52 weeks

  12. Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks

    Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

    Time frame: Up to Week 52

  13. Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.

    Time frame: Up to 52 weeks

  14. Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.

    Time frame: Up to 52 weeks

  15. Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 52 weeks

  16. Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 52 weeks

  17. Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

    Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

    Time frame: Up to Week 52

  18. Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

    Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

    Time frame: Up to Week 52

  19. Change From Baseline in Fasting Lipids at Week 24

    Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.

    Time frame: Baseline (Day 1) and Week 24

  20. Change From Baseline in Fasting Lipids at Week 48

    Lipid parameters included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides.

    Time frame: Baseline (Day 1) and Week 48

  21. Number of Participants With Observed Genotypic and Phenotypic Resistance to Antiretrovirals (ARVs) for Participants Meeting Confirmed Virologic Withdrawal (CVW) Criteria

    Genotypic and phenotypic testing was conducted for participants who met the CVW criteria, i.e., one assessment with HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL at any point in the study.

    Time frame: Up to week 48

  22. Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24

    The HIV Treatment Satisfaction Questionnaire (HIVTSQ) is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.

    Time frame: Baseline (Day 1) and Week 24

  23. Change From Baseline in Health Status by HIV TSQ at Week 48

    The HIVTSQ is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.

    Time frame: Baseline (Day 1) and Week 48

  24. Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24

    SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

    Time frame: Baseline (Day 1) and Week 24

  25. Change From Baseline in Health Status by SDM at Week 48

    SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

    Time frame: Baseline (Day 1) and Week 48

  26. Change From Baseline in Health Status by SDM in Continuation Phase

    SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

    Time frame: Baseline (Day 1) and Week 76, Week 100, and Week 132

07

Results

Posted Jul 1, 2022

Participant flow

The study consist of two phases - Randomized phase and Continuation phase.

Randomized Phase (Day1 to Week 52)
Participant flow — Randomized Phase (Day1 to Week 52)
MilestoneRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARContinuation Phase-Participants Who Received DTG/3TC FDC
Started2462470
Completed1362290
Not completed110180
Withdrew: Adverse event430
Withdrew: Lack of efficacy030
Withdrew: Lost to follow-up210
Withdrew: Death100
Withdrew: Physician decision120
Withdrew: Withdrawal by subject150
Withdrew: Transferred to continuation phase9600
Withdrew: Protocol deviation540
Continuation Phase (Week 52 to Week 132)
Participant flow — Continuation Phase (Week 52 to Week 132)
MilestoneRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARContinuation Phase-Participants Who Received DTG/3TC FDC
Started0096
Completed0091
Not completed005
Withdrew: Physician decision001
Withdrew: Lost to follow-up001
Withdrew: Lack of efficacy001
Withdrew: Adverse event002

Outcome measures

PrimaryNumber of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48

Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 4813
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Adjusted difference in percent (adp): -0.8 · 95% CI -2.4 to 0.8ADP was based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factor:Baseline third agent (protease inhibitor \[PI\], non-nucleoside reverse transcriptase inhibitor \[NNRTI\], and integrase inhibitor \[INI\]).
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48

Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48232229
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Adjusted difference in percent: 1.6 · 95% CI -2.8 to 5.9ADP was based on Cochran-Mantel Haenszel stratified analysis adjusting for Baseline stratification factor:Baseline third agent (PI, NNRTI, and INI).
SecondaryNumber of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24

Number of participants with plasma HIV 1 RNA \>=50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 2401
SecondaryNumber of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24

Number of participants with plasma HIV 1 RNA \<50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant's virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot ("No virologic data") is not pre-defined as an endpoint and therefore not reported separately.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24234237
SecondaryChange From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Median · cells/cubic millimeter (cells/mm^3)
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24
cells/cubic millimeter (cells/mm^3)Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 2430.5 (-71.5 to 111)10 (-79 to 95)
SecondaryChange From Baseline in CD4+ Cell Count for Week 48

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Median · cells/mm^3
Change From Baseline in CD4+ Cell Count for Week 48
cells/mm^3Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in CD4+ Cell Count for Week 4830 (-83 to 115.5)2 (-105 to 94)
SecondaryChange From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24

CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Median · Ratio
Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24
RatioRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24-0.02 (-0.105 to 0.07)0.01 (-0.06 to 0.09)
SecondaryChange From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48

CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Median · Ratio
Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48
RatioRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 480.04 (-0.06 to 0.13)0.05 (-0.06 to 0.13)
SecondaryNumber of Participants With Disease Progression Through Week 24

Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.

Time frame:
Up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression Through Week 24
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Disease Progression Through Week 2400
SecondaryNumber of Participants With Disease Progression Through Week 48

Participants with disease progression included incidences of HIV-associated conditions, AIDS and death. HIV-associated conditions were assessed according to the 2014 HIV infection by CDC classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression Through Week 48
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Disease Progression Through Week 4810
SecondaryNumber of Participants With Adverse Events (AEs) and AEs Leading to Discontinuation

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and AEs Leading to Discontinuation
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
AEs180172
AEs leading to discontinuation53
SecondaryNumber of Participants With AEs by Severity Grades

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs by Severity Grades
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Grade 19267
Grade 27786
Grade 31017
Grade 402
Grade 510
SecondaryNumber of Participants With Hepatobiliary Abnormalities Through 52 Weeks

Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN00
ALT >=3xULN & ALP <2xULN & BIL >=2xULN00
ALT >=3xULN & BIL >=1.5xULN00
AST >=3xULN & BIL >=2xULN00
AST >=3xULN & ALP <2xULN & BIL >=2xULN00
AST >=3xULN & BIL >=1.5xULN00
ALT+AST >=20xULN00
ALT+AST >=10xULN00
ALT+AST >=5xULN00
ALT+AST >=3xULN32
ALT >=20xULN00
ALT >=10xULN00
ALT >=5xULN11
ALT >=3xULN65
AST >=20xULN00
AST >=10xULN00
AST >=5xULN10
AST >=3xULN52
BIL >=2xULN05
BIL >=1.5xULN07
ALP >=1.5xULN48
ALT >=3xULN - <5xULN54
ALT >=5xULN - <10xULN11
ALT >=10xULN - <20xULN00
Hepatocellular injury51
Hepatocellular injury and BIL >=2xULN00
SecondaryNumber of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Any Event13
Grade 111
Grade 202
Grade 300
Grade 400
Grade 500
SecondaryNumber of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Any Event179169
Grade 19166
Grade 27784
Grade 31017
Grade 402
Grade 510
SecondaryNumber of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^201
SecondaryNumber of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^252
SecondaryNumber of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2

Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN00
ALT >=3xULN & ALP <2xULN & BIL >=2xULN00
ALT >=3xULN & BIL >=1.5xULN00
AST >=3xULN & BIL >=2xULN00
AST >=3xULN & ALP <2xULN & BIL >=2xULN00
AST >=3xULN & BIL >=1.5xULN00
ALT+AST >=20xULN00
ALT+AST >=10xULN00
ALT+AST >=5xULN00
ALT+AST >=3xULN00
ALT >=20xULN00
ALT >=10xULN00
ALT >=5xULN00
ALT >=3xULN00
AST >=20xULN00
AST >=10xULN00
AST >=5xULN00
AST >=3xULN00
BIL >=2xULN01
BIL >=1.5xULN01
ALP >=1.5xULN00
ALT >=3xULN - <5xULN00
ALT >=5xULN - <10xULN00
ALT >=10xULN - <20xULN00
Hepatocellular injury00
Hepatocellular injury and BIL >=2xULN00
SecondaryNumber of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2

Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\[ALT/ALT ULN\]/\[ALP/ALP ULN\]) \>= 5 and ALT \>=3xULN.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2
ParticipantsRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
ALT >=3xUpper Limit of Normal (ULN) & BIL >=2xULN00
ALT >=3xULN & ALP <2xULN & BIL >=2xULN00
ALT >=3xULN & BIL >=1.5xULN00
AST >=3xULN & BIL >=2xULN00
AST >=3xULN & ALP <2xULN & BIL >=2xULN00
AST >=3xULN & BIL >=1.5xULN00
ALT+AST >=20xULN00
ALT+AST >=10xULN00
ALT+AST >=5xULN00
ALT+AST >=3xULN32
ALT >=20xULN00
ALT >=10xULN00
ALT >=5xULN11
ALT >=3xULN65
AST >=20xULN00
AST >=10xULN00
AST >=5xULN10
AST >=3xULN52
BIL >=2xULN04
BIL >=1.5xULN06
ALP >=1.5xULN48
ALT >=3xULN - <5xULN54
ALT >=5xULN - <10xULN11
ALT >=10xULN - <20xULN00
Hepatocellular injury51
Hepatocellular injury and BIL >=2xULN00
SecondaryChange From Baseline in Fasting Lipids at Week 24

Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · milligram/deciliter (mg/dL)
Change From Baseline in Fasting Lipids at Week 24
milligram/deciliter (mg/dL)Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Serum or Plasma Triglycerides (mg/dL)-4.944 ± 56.4947-3.571 ± 61.9494
Serum or Plasma HDL Cholesterol, Direct (mg/dL)-0.326 ± 9.17370.585 ± 8.3277
Serum or Plasma Cholesterol (mg/dL)-3.096 ± 31.66340.058 ± 25.8019
Serum or Plasma LDL Cholesterol (Calculated or Direct), (mg/dL)-1.64 ± 25.5153-0.06 ± 19.802
SecondaryChange From Baseline in Fasting Lipids at Week 48

Lipid parameters included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Lipids at Week 48
mg/dLRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Serum or Plasma Triglycerides (mg/dL)-3.112 ± 66.9065-4.002 ± 71.0132
Serum or Plasma HDL Cholesterol, Direct (mg/dL)-0.809 ± 10.56510.688 ± 8.5584
Serum or Plasma Cholesterol (mg/dL)0.131 ± 30.2712.668 ± 27.0351
Serum or Plasma LDL Cholesterol (Calculated or Direct), (mg/dL)1.753 ± 22.85852.734 ± 20.0256
SecondaryNumber of Participants With Observed Genotypic and Phenotypic Resistance to Antiretrovirals (ARVs) for Participants Meeting Confirmed Virologic Withdrawal (CVW) Criteria

Genotypic and phenotypic testing was conducted for participants who met the CVW criteria, i.e., one assessment with HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL at any point in the study.

Time frame:
Up to week 48

No measurements were reported for this outcome.

SecondaryChange From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24

The HIV Treatment Satisfaction Questionnaire (HIVTSQ) is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24
Scores on a scaleRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 242.9 ± 5.851 ± 5.16
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Mixed Model Repeated Measures · p = <0.001 · Adjusted mean: 1.4 · 95% CI 0.7 to 2.2MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Age (continuous), Sex, Race, Baseline Value (continuous), Treatment by Visit interaction, Baseline Value by Visit interaction, with Visit as the repeated factor.
SecondaryChange From Baseline in Health Status by HIV TSQ at Week 48

The HIVTSQ is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status by HIV TSQ at Week 48
Scores on a scaleRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in Health Status by HIV TSQ at Week 482.9 ± 61 ± 5.14
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Mixed Model Repeated Measures · p = <0.001 · Adjusted mean: 1.4 · 95% CI 0.7 to 2.2MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Age (continuous), Sex, Race, Baseline Value (continuous), Treatment by Visit interaction, Baseline Value by Visit interaction, with Visit as the repeated factor.
SecondaryChange From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24

SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24
Scores on a scaleRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24-2.6 ± 8.69-0.7 ± 8.01
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Mixed Model Repeated Measures · p = 0.021 · Adjusted mean: -1.6 · 95% CI -2.9 to -0.2MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Age (continuous), Sex, Race, Baseline Value (continuous), Treatment by Visit interaction, Baseline Value by Visit interaction, with Visit as the repeated factor.
SecondaryChange From Baseline in Health Status by SDM at Week 48

SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status by SDM at Week 48
Scores on a scaleRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CAR
Change From Baseline in Health Status by SDM at Week 48-2.4 ± 7.64-1.5 ± 7.92
Statistical analysis
  • Randomized Phase-Participants Who Received DTG/3TC FDC vs Randomized Phase-Participants Who Received CAR · Mixed Model Repeated Measures · p = 0.398 · Adjusted mean: -0.5 · 95% CI -1.8 to 0.7MMRM adjusted for following: Treatment, Visit, Baseline Third Agent Class, Age (continuous), Sex, Race, Baseline Value (continuous), Treatment by Visit interaction, Baseline Value by Visit interaction, with Visit as the repeated factor.
SecondaryChange From Baseline in Health Status by SDM in Continuation Phase

SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).

Time frame:
Baseline (Day 1) and Week 76, Week 100, and Week 132
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status by SDM in Continuation Phase
Scores on a scaleContinuation Phase-Participants Who Received DTG/3TC FDC
Week 76-4.1 ± 8.69
Week 100-3.4 ± 11.33
Week 132-6.1 ± 9.94

Adverse events

Collected over All-cause mortality, non-serious adverse events (non-SAEs) and serious adverse events (SAEs) were collected from day 1 to week 52 for Randomized Phase and from week 52 to week 132 for continuation phase.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Phase-Participants Who Received DTG/3TC FDC1/246 (0.4%)7/246 (2.8%)179/246 (72.8%)
Randomized Phase-Participants Who Received CAR0/247 (0%)16/247 (6.5%)169/247 (68.4%)
Continuation Phase-Participants Who Received DTG/3TC FDC0/96 (0%)1/96 (1%)43/96 (44.8%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARContinuation Phase-Participants Who Received DTG/3TC FDC
COVID-19Infections and infestations1/2463/2470/96
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2460/2471/96
Pneumonia bacterialInfections and infestations0/2462/2470/96
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/2460/2470/96
Anal abscessInfections and infestations1/2460/2470/96
CataractEye disorders1/2460/2470/96
DeathGeneral disorders1/2460/2470/96
Gastrointestinal stromal tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2460/2470/96
TracheitisInfections and infestations1/2460/2470/96
Acute myocardial infarctionCardiac disorders0/2461/2470/96
Most frequent other events
Showing 10 of 401
Most frequent other events
EventRandomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARContinuation Phase-Participants Who Received DTG/3TC FDC
Weight increasedInvestigations20/2465/2473/96
HeadacheNervous system disorders16/24617/2473/96
Upper respiratory tract infectionInfections and infestations11/24615/2473/96
COVID-19Infections and infestations14/2468/2473/96
Back painMusculoskeletal and connective tissue disorders14/2467/2473/96
InsomniaPsychiatric disorders14/2464/2471/96
DizzinessNervous system disorders13/2466/2471/96
AnxietyPsychiatric disorders5/2466/2475/96
HypercholesterolaemiaMetabolism and nutrition disorders3/2463/2475/96
HypertriglyceridaemiaMetabolism and nutrition disorders1/2465/2475/96

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARTotal
Mean45.5 ± 11.0445.8 ± 11.9945.7 ± 11.51
Sex: Female, Male
Sex: Female, Male(Participants)Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARTotal
Female10884192
Male138163301
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Randomized Phase-Participants Who Received DTG/3TC FDCRandomized Phase-Participants Who Received CARTotal
African American/African Heritage454893
American Indian OR Alaska Native181432
Asian - East Asian Heritage273663
Asian - South East Asian Heritage437
White - Arabic/North African Heritage7411
White - White/Caucasian/European Heritage142140282
Multiple325
08

Study locations

119 sites
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    San Francisco, California 94110, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20017, United States
  • GSK Investigational Site
    Pensacola, Florida 32503, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63108, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74127, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26506, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1425AWK, Argentina
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000PBJ, Argentina
  • GSK Investigational Site
    Buenos Aires, 1405, Argentina
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Salvador, Bahia 40110-060, Brazil
  • GSK Investigational Site
    Curitiba, Paraná 80060-900, Brazil
  • GSK Investigational Site
    Campinas, São Paulo 13015-080, Brazil
  • GSK Investigational Site
    Manaus, 69040-000, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21040-360, Brazil
  • GSK Investigational Site
    São Paulo, 01246-090, Brazil
  • GSK Investigational Site
    São Paulo, 04039-032, Brazil
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 0W5, Canada
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100069, China
  • GSK Investigational Site
    Chongqing, 400000, China
  • GSK Investigational Site
    Shanghai, 201508, China
  • GSK Investigational Site
    Aarhus, 8200, Denmark
  • GSK Investigational Site
    Hvidovre, 2650, Denmark
  • GSK Investigational Site
    Koebenhavn, DK-2100, Denmark
  • GSK Investigational Site
    Odense C, 5000, Denmark
  • GSK Investigational Site
    Bobigny, 93000, France
  • GSK Investigational Site
    Bordeaux, 33075, France
  • GSK Investigational Site
    Nice, 6202, France
  • GSK Investigational Site
    Orléans Cedex 2, 45067, France
  • GSK Investigational Site
    Paris, 75010, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Toulouse Cedex 9, 31059, France
  • GSK Investigational Site
    Tourcoing, 59208, France
  • GSK Investigational Site
    Muenchen, Bayern 80335, Germany
  • GSK Investigational Site
    München, Bayern 81675, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53105, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50668, Germany
  • GSK Investigational Site
    Koeln, Nordrhein-Westfalen 50674, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    München, 80336, Germany
  • GSK Investigational Site
    Modena, Emilia-Romagna 41100, Italy
  • GSK Investigational Site
    Roma, Lazio 00149, Italy
  • GSK Investigational Site
    Roma, Lazio 00168, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Bergamo, 24128, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45170, Mexico
  • GSK Investigational Site
    Distrito Federal, 06470, Mexico
  • GSK Investigational Site
    Ekaterinburg, 620149, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Tolyatti, 445846, Russian Federation
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Cape Town, 7505, South Africa
  • GSK Investigational Site
    Observatory, Cape Town, 7925, South Africa
  • GSK Investigational Site
    Badalona, Barcelona, 8916, Spain
  • GSK Investigational Site
    Cadiz, 11009, Spain
  • GSK Investigational Site
    Granada, 18016, Spain
  • GSK Investigational Site
    La Coruña, 15006, Spain
  • GSK Investigational Site
    Madrid, 28006, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Murcia, 30120, Spain
  • GSK Investigational Site
    Palma de Mallorca, 07198, Spain
  • GSK Investigational Site
    San Sebastian de los Reyes, 28702, Spain
  • GSK Investigational Site
    Santa Cruz de Tenerife, 38010, Spain
  • GSK Investigational Site
    Sevilla, 41013, Spain
  • GSK Investigational Site
    Valencia, 46014, Spain
  • GSK Investigational Site
    Göteborg, SE-416 85, Sweden
  • GSK Investigational Site
    Malmö, SE-205 02, Sweden

Showing the first 100 of 119 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. PubMed 35235656 ↗
  • Masters MC, Cohn SE. Two-drug HIV regimens: more data still needed. Lancet HIV. 2021 Aug;8(8):e454-e455. doi: 10.1016/S2352-3018(21)00106-5. No abstract available. PubMed 34358493 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Apr 2021, 17 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 17 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2019
First posted
Jul 16, 2019
StartActual
Nov 11, 2019
Primary completionActual
Apr 23, 2021
CompletionActual
Sep 9, 2022
Results first posted
Jul 1, 2022
Last update
Oct 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04021290
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline, PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Jul 16, 2019
Start date
Nov 11, 2019
Primary completion
Apr 23, 2021
Completion
Sep 9, 2022
Results posted
Jul 1, 2022
Last update
Oct 19, 2023

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dolutegravir · Lamivudine

Start the discussion